Xcout IntelACTINOGEN MEDICAL LIMITED competitors & alternatives
The 12 closest competitors and alternatives to ACTINOGEN MEDICAL LIMITED among pharmaceuticals, biotechnology & life sciences companies — ranked by similarity to what ACTINOGEN MEDICAL LIMITED actually does, not by market-cap band.
Subscribe to see ACTINOGEN MEDICAL LIMITED’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About ACTINOGEN MEDICAL LIMITED
Actinogen Medical Limited is an Australian biotechnology company dedicated to developing treatments for neurological and neuropsychiatric disorders linked to imbalanced brain cortisol levels. Their lead product, Xanamem, an inhibitor of the 11ß-HSD1 enzyme, is currently in Phase 2 clinical trials. This compound has demonstrated target engagement within the central nervous system and is being investigated for its potential in conditions such as Alzheimer's disease, depression with cognitive impairment, and the anxiety, sleep, and behavioral issues associated with fragile X syndrome. Founded in 1999, the company was formerly known as Actinogen Limited, adopting its current name in November 2015, and is headquartered in Sydney, Australia.
ACTINOGEN MEDICAL LIMITED at a glance
ACTINOGEN MEDICAL LIMITED is a pharmaceuticals, biotechnology & life sciences company headquartered in Sydney, Australia. It is publicly listed (ACW) with a market capitalisation of $121.6M. Xcout tracks 16 named people at ACTINOGEN MEDICAL LIMITED, including Dr Steven Gourlay (Managing Director Chief Executive Officer).
ACTINOGEN MEDICAL LIMITED leadership
- Dr Steven GourlayManaging Director Chief Executive Officer
- Will SouterChief Financial Officer
- Andrew (Andy) UdellChief Commercial Officer
- Dr Dana C. HiltChief Medical Officer
- Peter WebseCompany Secretary
- Dr Geoff BrookeIndependent Non-Executive Chair
10 more named people on record for ACTINOGEN MEDICAL LIMITED, with roles, board committees and tenure — see the full roster →
Top 12 ACTINOGEN MEDICAL LIMITED competitors
Ranked by semantic similarity — how close each company is to ACTINOGEN MEDICAL LIMITED by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals, biotechnology & life sciences company
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Hawthorn East, Australia.
Pharmaceuticals
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Similar pharmaceuticals, biotechnology & life sciences company
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Similar pharmaceuticals, biotechnology & life sciences company
Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Pharmaceuticals
Corcept Therapeutics Incorporated is a commercial-stage pharmaceutical company that develops and markets cortisol modulation therapies to treat serious medical conditions. The company focuses on modulating cortisol activity at the glucocorticoid receptor to create novel treatments across therapeutic areas such as endocrinology, oncology, metabolism, and neurology.
Similar pharmaceuticals, biotechnology & life sciences company
Invex Therapeutics Ltd is an Australian biopharmaceutical company dedicated to researching and developing innovative treatments for various neurological disorders. Their primary focus is Exenatide, a promising therapeutic agent aimed at neurological conditions linked to or resulting from elevated intracranial pressure, including idiopathic intracranial hypertension, acute stroke, and traumatic brain injury. Exenatide has successfully advanced through Phase II clinical trials. The company was founded in 2019 and operates from Perth, Australia.
Pharmaceuticals
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Similar pharmaceuticals, biotechnology & life sciences company
Percheron Therapeutics Limited, an Australian enterprise established in 2000 with its headquarters in Melbourne, is dedicated to the research and development of groundbreaking antisense pharmaceuticals. Formerly known as Antisense Therapeutics Limited until its name change in December 2023, the company holds a promising product portfolio. This includes ATL1102, an antisense inhibitor designed to target CD49d, which is currently undergoing Phase IIa clinical trials for the treatment of various inflammatory and muscular conditions such as Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, and asthma. Another key asset is Atesidorsen (ATL1103), an oligonucleotide that has finished Phase II clinical trials. Atesidorsen functions by blocking the growth hormone receptor, aiming to lower blood concentrations of insulin-like growth factor-I (IGF-I) and thereby address illnesses linked to an overabundance of growth hormone activity.
Pharmaceuticals
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Pharmaceuticals
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Pharmaceuticals
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. Leveraging its proprietary SupraAntigen and Morphomer platforms, the company engineers a range of vaccines, antibodies, and small molecules specifically designed to engage with aberrantly folded proteins implicated across various neurodegenerative disorders. Its pipeline features Crenezumab, a humanized, conformation-specific monoclonal antibody currently undergoing a Phase II clinical prevention trial for Alzheimer's disease (AD). Additionally, AC Immune is advancing ACI-24, an anti-Abeta vaccine candidate, which is in Phase II clinical evaluation for AD and has successfully completed a Phase Ib study for Down syndrome. Other key candidates include ACI-35, an anti-Tau vaccine candidate that has finished Phase Ib clinical assessment, and a Tau-positron emission tomography (PET) imaging tracer, also in Phase II development. Furthermore, the company is engaged in the research and development of small molecule inhibitors to prevent Tau aggregation, targeting AD and various NeuroOrphan indications. Early-stage efforts include discovery and preclinical programs for a spectrum of neurodegenerative diseases, encompassing diagnostic agents aimed at TDP-43, alpha-synuclein, and NLRP3. The company maintains strategic partnerships and licensing agreements with key industry players such as Genentech, Inc., Biogen International GmbH, Janssen Pharmaceuticals, Inc., Life Molecular Imaging SA, Eli Lilly and Company, and WuXi Biologics. Founded in 2003, AC Immune S.A. is headquartered in Lausanne, Switzerland.
Similar pharmaceuticals, biotechnology & life sciences company
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of ACTINOGEN MEDICAL LIMITED and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for ACTINOGEN MEDICAL LIMITEDand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →